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Abstract
T cell protein tyrosine phosphatase (TC-PTP / PTPN2) is an enzyme that is essential for the proper functioning of the immune
system and that participates in the control of cell proliferation, and inflammation. We previously observed that TC-PTP
2/2
mice display various immunodeficiencies, hypersensitivity to LPS and die within three weeks of birth due to anemia and
widespread inflammation. A recent analysis of the Wellcome Trust Case Control Consortium (WTCC) genome wide scan
data, reported in 2007, indicated a potential role for TC-PTP in inflammatory bowel disease (IBD). To further investigate the
potential role of TC-PTP in IBD, we studied heterozygous TC-PTP mutant mice challenged with dextran sulfate sodium (DSS)
in their drinking water. In comparison to control animals, we observed significant changes in the colon mucosa of DSS-
treated TC-PTP
+/2 mice, in the ratio of colon to body weight, as well as an up-regulation of mRNA transcripts for IL-6, IL-23,
1L-12b, IFN-c, TNF-a. Moreover, up-regulation of serum IL-6 levels in DSS-treated TC-PTP
+/2 mice confirms that mice with a
single copy of the TC-PTP gene display increased susceptibility to systemic inflammation due to bowel epithelial erosion
resulting from DSS challenge. Our findings support the lack of modulation of Janus kinases 1 and 3 (Jak1, Jak3), and the
downstream signal transducer and activator of transcription 1,3 and 5 (Stat1, Stat3, Stat 5) by PTPN2 in the development of
IBD like condition. Pathological and molecular analysis reveal that the deficiency of TC-PTP results in pro-inflammatory
condition in the bowel of heterozygous TC-PTP
+/2 mice. These novel findings in TC-PTP hemi-deficiency support the
hypothesis that TC-PTP is an important regulator of inflammatory cytokine signaling and that it may be implicated in the
pathophysiology of IBD.
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Introduction
Ulcerative colitis and Crohn’s disease are the main two types of
inflammatory bowel disease (IBD). Colitis is a well established risk
factor for the development of colorectal cancer, the 3rd leading
cause of cancer in North America in both men and women with
respect to both the incidence rate and estimated death rates [1,2].
IBDis associated with bothcolitis and ileitis. [1,3–7].The cause(s) of
colitis in IBD remains unknown, although many theories have been
proposed, and links with genetic loci have been postulated.
Individuals with IBD tend to have abnormalities of the immune
system. More than 1 million Americans and more than 2 millions
Europeans suffer from IBD [1]. Crohn’s Disease, the 3
rd ranking
disease in a genome-wide association study performed by the
Wellcome Trust Case Control Consortium (WTCC) in 2007 [2],
was found associated with a SNP in a region of chromosome 18p11
with the only gene lying in this region being PTPN2, the encoding
locus for the T-cell protein tyrosine phosphatase (TC-PTP) [2].
Moreover, other recent genetic studies have also shown links
between IBD and the TC-PTP (PTPN2) locus [1–7].
TC-PTP is a classical non-receptor protein tyrosine phosphatase
that can regulate pro-inflammatory cytokine signaling [8]. PTPN2-
knockout mice have altered hematopoiesis affecting several
lineages [9] and develop severe inflammation within two weeks
of birth [8–11]. TC-PTP was one of the first members of the PTP
gene family identified. Although originally cloned from a T cell
cDNA library, it is ubiquitously expressed at all stages of
mammalian development and in most embryonic and adult tissues
[12]. The mouse isoform of TC-PTP was later cloned in 1992
[13]. PTPN2 is located on chromosomal region 18p11.2–11.3 in
humans and in a syntenic region in mice [14]. The 45 kDa form of
TC-PTP (45 kDa) contains a nuclear localization signal N-
terminal to its catalytic domain, and is encoded by the main
detectable splice form in mice [13].
The systemic inflammation in TC-PTP
2/2 mice and various
genetic studies focusing on the association of the PTPN2 locus with
IBD led to the hypothesis that the absence of the enzymatic
activity or decreased expression of TC-PTP may play a role in
many chronic inflammatory conditions. We evaluated the role
of TC-PTP as a modulator of inflammation in IBD relevant
PLoS ONE | www.plosone.org 1 January 2010 | Volume 5 | Issue 1 | e8868conditions in vivo, using a dextran sulfate sodium (DSS)-induced
colitis mouse model. DSS causes direct damage to the epithelial
barrier of the colon leading to cellular dysfunction, impaired
epithelial repair and altered epithelial barrier [15,16]. We
compared TC-PTP
+/2 and wild-type mice treated with dextran
sulfate sodium verses non-treated controls [15,16]. We observed
that TC-PTP
+/2 mice were more sensitive to DSS treatment than
TC-PTP
+/+ mice as shown by histopathological alterations of large
bowel, increased cytokine expression in serum and cytokine
signaling in the large bowel. Heterozygosity of TC-PTP may thus
prime the immune system to respond more readily to irritants such
as DSS resulting in a more severe inflammatory condition. This
may partially explain the association of TC-PTP with chronic
inflammatory diseases such as IBD [1–7]. TC-PTP is a key
modulator in inflammation, and by detecting or controlling its
expression or downstream events we may open new avenues in the
diagnosis and treatments of inflammatory bowel diseases like
colitis.
Results
Increased Weight Loss and Decreased Colon Weight of
TC-PTP
+/2 Mice during DSS-Induced Colitis
To evaluate the role of TC-PTP in bowel inflammation, we
treated wild type (WT) and heterozygous TC-PTP
+/2 mice with
DSS to induce colitis. We compared four groups of animals: DSS-
treated TC-PTP
+/2 and TC-PTP
+/+ mice, and non-treated TC-
PTP
+/2 and TC-PTP
+/+ mice. TC-PTP
2/2 mice were not
subjected to DSS-treatment as they die shortly after weaning
[8–11] and cannot live long enough to complete the course of DSS
treatment. However, untreated TC-PTP
2/2 mice were used as
controls in some experiments.
We observed a significant decrease in the body weight of DSS-
treated TC-PTP
+/2 mice compared to DSS-treated TC-PTP
+/+
mice (*p,0.001). In addition there was a decrease in body weight
in DSS-treated TC-PTP
+/2 mice, throughout the course of DSS
treatment, in comparison to non-treated TC-PTP
+/2 (*p,0.001)
and TC-PTP
+/+ (***p,0.0002) (Figure 1A). Furthermore the ratio
of colon to body weight of DSS-treated TC-PTP
+/2 mice was
significantly lower than those of DSS-treated TC-PTP
+/+ mice
(* p,0.05) (Figure 1B). Similarly, a significant decrease in colon to
body weight ratio was observed in DSS-treated TC-PTP
+/2 mice
in comparison to non-treated TC-PTP
+/2 mice (*** p,0.001), as
well as in DSS-treated TC-PTP
+/+ compared to non-treated
TC-PTP
+/+ mice (*** p,0.001).
DSS-Treated TC-PTP
+/2 Colons Display Histological
Alterations and Elevation of Peripheral Blood
Lymphocytes and Neutrophils
To further investigate the phenotypes seen in DSS-treated TC-
PTP heterozygous mice, we evaluated the degree of inflammatory
activity by histo-pathological examination of the colons from
animals with the different genotypes. Colon tissue sections on WT
controls demonstrated normal crypt parallelism and intact surface
epithelium (Figure 2A, B and C). Tissues collected from DSS-
treated mice demonstrated crypt distortion and neutrophilic
infiltration (Figure 2A, B and C). Alterations in morphology
during colonic injury in DSS-treated TC-PTP
+/2 mice compared
to DSS-treated TC-PTP
+/+, non-treated TC-PTP
+/2 and non-
treated TC-PTP
+/+ mice showed significant increase in epithelial
erosion and crypt damage, as shown in (Figure 2C). Colons from
DSS-treated TC-PTP
+/2 mice also showed significantly more
pronounced decrease in number of crypts (p,0.001), crypt width
(p,0.003), crypt height (p,0.005) and epithelial height (p,0.0002)
as compared to DSS-treated TC-PTP
+/+, as shown in Figure 2C.
Histo-pathological scoring for assessment of inflammatory changes
was 32 out of a maximum of 40 in DSS-treated TC-PTP
+/2 mice,
compared to 12 in DSS-treated TC-PTP
+/+,( p,0.0003), as shown
in Figure 3B. Likewise, differential peripheral white blood cell
counts revealed a significant increase in lymphocyte (p,0.0114)
and neutrophils (p,0.0001) counts in DSS-treated TC-PTP
+/2
mice compared to DSS-treated TC-PTP
+/+ (Figure 3A).
Hyperactivation of STAT and JAKs in TC-PTP
+/2 Colon
upon DSS-Treatment
Key signaling molecules involved in the inflammatory process
includes the janus kinases (Jaks) and the downstream effectors
signal transducers and activators of transcription (STATs). Since
Figure 1. Increased response to DSS treatment in the presence
of only one allele of TC-PTP. A. Increased weight loss of TC-PTP
+/2
mice during DSS-induced colitis. At 19 days of age mouse body weight
was 11–12 g followed by DSS treatment. Body weight of DSS-treated
TC-PTP
+/2 (Het-DSS) (2.5860.4) mice were significantly lower than,
TC-PTP
+/2 (Het) (5.060.8) and TC-PTP
+/+ (WT-DSS) (3.7860.5) mice
***p,0.0002. DSS-treated TC-PTP
+/2 mice compared to DSS-treated
TC-PTP
+/+ mice *p,0.001. Data represent the mean of three groups
of three animals each (N=9). B. Ratio of colon weight of DSS-treated
TC-PTP
+/2 (Het-DSS) mice were significantly lower than DSS-treated
TC-PTP
+/+ (WT-DSS) mice p,0.05. In the case of TC-PTP
+/2 (Het) vs. DSS-
treated TC-PTP
+/2 (WT-DSS) mice p,0.001, and p,0.001 in comparison
of TC-PTP
+/+ vs. DSS-treated TC-PTP
+/+ mice.
doi:10.1371/journal.pone.0008868.g001
IBD with DSS in TC-PTP
+/2 Mice
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and given that DSS-induced colitis is known to trigger inflamma-
tion in the bowel and activate these pathways [8–11], we
examined the phosphorylation status of various Jaks and
STATs in colonic cells from mice of various TC-PTP genotypes
challenged with DSS treatment. Hence, bowel sections were
isolated for immunoblotting. DSS treatment in TC-PTP
+/2 mice
results in hyper-phosphorylation of JAK1, JAK3, STAT1, STAT3
and STAT5 while there was a decrease in JAK2 activity (Figure 4).
Interestingly, both TC-PTP
+/+ and TC-PTP
+/2 mice showed a
decrease in protein levels of TC-PTP in the bowel following DSS
treatment with levels being at the limit of detection by Western
blotting in treated TC-PTP
+/2 mice.
Up-Regulation of Pro-Inflammatory Cytokines in the
Colon of DSS-Treated TC-PTP
+/2 Mice
Since there was hyper-activation of several STATs and JAKs
mediators, we measured the expression of several corresponding
downstream pro-inflammatory cytokines using RT-PCR. Colonic
extracts from heterozygous TC-PTP mice treated with DSS
showed up-regulation of TNFa, IFNc, IL-12 b, IL-23R and IL-6
(Figure 5). Levels of these cytokines were significantly higher in
DSS-treated TC-PTP
+/2 mice and untreated TC-PTP
2/2 (KO,
used as a control) mice compared to WT mice, TC-PTP
+/2 (DSS
non treated) and WT (DSS-treated).
Based on published evidence that Jaks and STAT pathways
negatively regulate inflammatory bowel diseases like colitis in
Crohn’s disease and ulcerative coloitis [1–7], we pursued the
possibility that DSS treatment was also initiating systemic
inflammation in TC-PTP
+/2 mice. Therefore, we measured the
levels of IL-6, IL-12p40, IFN-c and TNF-a in the serum of DSS-
treated TC-PTP
+/2 and TC-PTP
+/+ mice as well as non-treated
control animals. Of the cytokines analyzed, we were able to detect
a 4.2-fold increase in serum IL-6 concentration in the TC-PTP
+/2
mice treated with DSS compared to TC-PTP
+/+ mice treated with
DSS (p,0.05) (Figure 6).
Figure 2. Loss of colorectal crypt-villi. A. Histopathological features of the mouse colon in association with colitis. Bar=1000 mm. From top to
bottom: TC-PTP
+/+(WT), TC-PTP
+/2 (Het), DSS-treated TC-PTP
+/+(WT-DSS) and DSS-treated TC-PTP
+/2 (Het-DSS). In TC-PTP
+/+(WT) crypts are straight and
the base of the glands reach the muscularis mucosae. Crypt-villus axes are normal and epithelium layer is intact. In DSS-treated TC-PTP
+/2 (Het-DSS) mice
ingestionofDSS causedcrypt destruction, Numerousneutrophils were presentinthe section(arrows). Lossofthe surface epitheliallayer is obvious, while
changes in crypt-villus axis and colon tissue architecture are observed. B. The number of crypts per field, field is 1000 mm in colorectal section of bowel.
The number of crypts in DSS-treated TC-PTP
+/2 (Het-DSS) mice were significantly lower than DSS-treated TC-PTP
+/+ (WT-DSS) mice p,0.002. C. Crypts in
field, crypts width, crypts height and epithelial height were quantified. Data represent mean and SD of three groups of three animal each (N=9).
doi:10.1371/journal.pone.0008868.g002
IBD with DSS in TC-PTP
+/2 Mice
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Much effort has recently been invested in identifying new
associations between gene expression and complex disease traits
such as in IBD. Recently, the Wellcome Trust Case Control
Consortium and other groups identified SNPs associated with
IBD in close proximity to the TC-PTP locus [1–7]. Given these
results, and the systemic inflammatory phenotype identified in
TC-PTP
2/2 mice [8], we used a well established model of
experimental colitis to study the role of TC-PTP in bowel
inflammation. Since the homozygous TC-PTP
2/2 phenotype is
lethal at approximately 3 weeks of age, we focused our efforts on
the hemizygous TC-PTP knock-out animals [8]. The gene dosage
reduction of TC-PTP enzyme in heterozygous mice was associated
with an increased susceptibility to DSS-induced colitis. DSS-
treated TC-PTP
+/2 mice lost more body and bowel weight
than control animals (Figure 1). They showed more pronounced
decrease in number, height and width of colonic crypts (Figure 2),
and higher histo-pathological scoring of colonic inflammatory
changes (Figure 3). Also, DSS-treatment in TC-PTP
+/2 mice was
found to result in colonic hyper-phosphorylation of the transduc-
tion pathway mediators JAK1, JAK3, STAT1, STAT3 and
Figure 3. Blood cell counts and histological analysis of colons.
A. Increase in numbers of lymphocytes p,0.0114 and neutrophils
p,0.0001 in DSS-treated TC-PTP
+/2 mice compared to DSS-treated TC-
PTP
+/+. B. The mean histology activity scores of colon tissue sections of
TC-PTP
+/+(WT) (0.360.34), TC-PTP
+/2 (Het) (760.55), DSS-treated TC-
PTP
+/+(WT-DSS) (1260.48) and DSS-treated TC-PTP
+/2(Het-DSS)
(3260.67) mice. Analysis was performed blinded by pathologist on a
scale from 0 to 40 (see Methods).
doi:10.1371/journal.pone.0008868.g003
Figure 4. Jak/Stat signaling pathways. Immunoblotting was used
to observe total protein levels and protein phosphorylation levels of
JAK1, JAK3, STAT1, STAT3 and STAT5.
doi:10.1371/journal.pone.0008868.g004
Figure 5. Colonic up-regulation of cytokines mRNA expression.
DSS-treated TC-PTP
+/2(Het-DSS) mice showed up-regulation of TNFa,
IFNc, IL-12 b, IL-23R and IL-6. Untreated TC-PTP
2/2 (null) mouse colon
mRNA was used as a control.
doi:10.1371/journal.pone.0008868.g005
IBD with DSS in TC-PTP
+/2 Mice
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as well as up-regulation of mRNA transcripts for TNFa, IFNc, IL-
12 b, IL-23R and IL-6 (Figure 5). Systemically, we detected a
significant increase in peripheral blood lymphocyte and neutrophil
counts (Figure 3) and a significant increase in serum IL-6
concentration in the DSS-treated TC-PTP
+/2 mice.
Taken together, these novel results indicate that DSS colitis
inflammation is more severe in TC-PTP
+/2 mice than in control
animals. This is accompanied by a marked increase in local
expression of TC-PTP regulated inflammation mediators and a
concomitant further decrease in TC-PTP expression. This local
inflammation is associated with a systemic inflammatory response
characterized by an elevation in serum IL-6 levels and increased
peripheral blood. Thus, not only TC-PTP
+/2 mice are more
sensitive to DSS-induced colitis, but they also respond more
severely to DSS-treatment both at the local and systemic levels.
Noteworthy, the overexpression of mRNA transcripts of IFN-c,
TNF-a and IL-12, and the systemic increase in IL-6 serum levels
observed in DSS-treated TC-PTP
+/2 mice are similar to those
observed in control TC-PTP
2/2 mice. The over-expression of
TH1 cytokines has previously been associated with Crohn’s disease
[8] [17]. Increased levels of those pro-inflammatory cytokines are
a major factor in organ-specific autoimmune inflammation [3,7].
Looking at events downstream from cytokine production, analysis
of the status of signal transducers revealed increased phosphory-
lation of Jak1 and Jak3 and of their substrates STAT1, STAT3
and STAT5 in DSS-treated TC-PTP
+/2 mice in a manner
reminiscent to what is observed in TC-PTP
2/2 mice [8].
In the DSS-induced colitis mouse model, initial injury leads to
its disruption and to the entry of bacteria into the intestinal wall
and into the blood stream. Supporting evidence for this comes
from rats treated with DSS which demonstrated higher level of
endotoxin in the portal blood than control animals [18]. Bacterial
invasion of the colonic wall and consequent production of
endotoxins such as LPS in turn cause the recruitment and
activation of inflammatory cells and result in the upregulation of
multiple inflammatory cytokines (Figure 5) [18] [17,19]. One
phenomenon occurring in DSS-treated TC-PTP
+/2 mice as well
as in patients with Crohn’s disease is the over-production of IL-6
[20] [21] [22]. Indeed, levels of IL-6 correlate with disease severity
in humans [23]. Binding of IL-6 to its receptor initiates cellular
events, including activation of Jak kinases. Jaks are a class of
tyrosine kinases that associate with cytokine receptors and are able
to phosphorylate and activate STAT proteins, which then
dimerize and enter the nucleus to activate the transcription of
target genes [24]. Jaks 1 and 3 have been identified as substrates of
TC-PTP downstream of IL-2 signaling in substrate-trapping
experiments using hematopoietic cell lines [25]. Downstream of
Jak activation, STATs are phosphorylated and can thus be
modified by PTPs to downregulate their action [26]. For instance,
IL-6-induced activation of STAT3 was suppressed by over
expression of the nuclear isoform of TC-PTP [27]. Thus, TC-
PTP function has an important impact on the sensitivity of the
innate immune system to bacterial antigens such as LPS [8], TC-
PTP
2/2 macrophages are hypersensitive to LPS and respond
by producing exaggerated amounts of interferon-alpha (IFN-a),
tumor necrosis factor-gamma (TNF-c), interleukin-12 (IL-12), and
nitric oxide (NO) [28]. Likewise, cells lacking TC-PTP produced
increased levels of IL-6 upon TNF-alpha (TNF-a) treatment [29].
TC-PTP
2/2 bone marrow-derived macrophages have elevated
levels of phosphorylated Jak 1 upon IFN-gamma (IFN-c)
stimulation [25].
Here we show that a gene dosage reduction of TC-PTP enzyme
in heterozygous TC-PTP
+/2 mice directly affects the intensity of
the inflammatory response to colonic mucosal injury. This is
mediated by an increased production of cytokines, including IL-6,
which in all likelihood results directly from the hemi-deficiency in
TC-PTP. Increased cytokine levels result in increased phosphor-
ylation of Jaks tyrosine kinases, which in turn phosphorylate/
activate signal transducers and activators of transcription (STATs).
Owing to the hemi-deficiency of TC-PTP in TC-PTP
+/2 mice,
normal targets for TC-PTP dephosphorylation, i.e. Jak-1, Jak3,
and STAT1, STAT3 and STAT5 [9] , remain aberrantly
activated, leading to an exaggerated inflammatory response. Our
novel findings open the way for future studies examining the
unexpected decrease in TC-PTP
+/2 protein levels following DSS
treatment, as well as identifying specific mechanisms leading to the
loss of epithelial cells in this animal model of IBD. Furthermore we
will be able to investigate whether epithelial cell death is secondary
to the decreased expression of TC-PTP in hemi-deficiency using
isolated colonic epithelial cells and in particular, mucosal immune
cells (lamina propria mononuclear cells/LPMC or lamin propria
Tcells/LPT). By inference, human beings with a constitutively less
active or less abundant TC-PTP enzyme might be more
susceptible to exaggerated bowel inflammation in case of bowel
mucosal injury. This hypothesis is consistent with WTCC’s
observation of Crohn’s disease being associated with SNPs
mapping near the TC-PTP gene locus.
Materials and Methods
Animal Model
Mice. Experiments were performed with Balb/c mice [10].
TC-PTP
+/+ and TC-PTP
+/2mice were obtained from hetero-
zygous mating and genotyped by Southern blotting as previously
described [10]. All mice were kept in specific pathogen-free
housing in the animal care facility.
Ethics Statement
All procedures were reviewed and approved from the McGill
University Animal Care Ethics committee.
Induction of Colitis
TC-PTP
+/+ and TC-PTP
+/2 mice, 19 days old and 11–12g in
body weight, were administered 5% dextran sulfate sodium (DSS)
Figure 6. IL-6 serum level in DSS-treated and control mice.
Serum was collected at the time of euthanasia and analyzed for
cytokine levels using Mouse Cytokine Multiplex Assay. A 4.2-fold
increase in serum IL-6 concentration in the TC-PTP
+/2(Het-DSS)
(11.667.6 pg/ml) compared to TC-PTP
+/+ (WT-DSS) (2.662.4 pg/ml)
mice (p,0.05).
doi:10.1371/journal.pone.0008868.g006
IBD with DSS in TC-PTP
+/2 Mice
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10 days, after which hydration with regular water was resumed for
1 day before they were weighted and humanely sacrificed (approx.
age 30 days) [15,16]. Animals were weighed daily and monitored
for rectal bleeding, diarrhea, and general signs of morbidity.
Control animals were given normal drinking water.
Histology
Evaluation of inflammation activity. The large intestine
was excised, and the colon weight was measured. The distal
(2.2,2.4 cm) of the colon was transected, flushed with PBS and
areas of redness for gross inflammation were recorded. The
macroscopic appearance of the colon was scored in a blinded
fashionasfollows:0,noevidenceofinflammation;1,erythemaonly;
2, erythema and small erosions; 3, 2 or more bleeding ulcers and/or
inflammation and/or moderate adhesions [30]. Tissues were then
fixed with 4%formaldehyde overnight. After overnight dehydration
and paraffin impregnation, tissues were embedded in a paraffin
block and serially sectioned. The 5-mm-thick sections were cut and
stained with hematoxylin and eosin (H & E) .The sections were
microscopically examined for histopathological changes, inflam-
mation severity was scored by a blinded pathologist.
Blood Count
Blood samples were taken at the end of the experiments by
cardiac puncture (heart blood) for blood count using an automatic
cytometer following manufacturer protocol (Beckmann Coulter,
Germany).
Histological Scoring
Analysis was performed blinded by pathologist and each
specimen was scored on a scale from 0 to 40 as follows: severity
of inflammation (0–3: none, slight, moderate, severe), epithelial
erosion (0–3: none, none, slight, moderate, severe), and crypt
damage (0–4: none, basal 1/3 damaged, basal 2/3 damaged, only
surface epithelium intact, entire crypt and epithelium lost). Each
score was then multiplied by a factor equivalent with the
percentage of tissue involvement (61: 0–25%, 62: 26–50%, 63:
51–75%, 64: 76–100%) [31] [32].
Immunoblotting
Large bowel lysate was collected after crushing tissues in liquid
nitrogen. Protein samples were resolved on 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and sub-
jected to immunoblotting. TC-PTP was detected using a monoclo-
nal antibody 3E2 as described in [33]. Phosphorylated Jak1, Jak2,
Jak3, Stat1, Stat3 and Stat5 proteins were detected using polyclonal
antibodies (Cell Signaling Technology). Total Jak1, Jak2, Jak3,
Stat1, Stat3 and Stat5 proteins were detected using polyclonal
antibodies (Cell Signaling Technology). Calnexin and b-Actin
monoclonal antibody were used as loading control for protein
samples (Sigma, Oakville, ON, Canada). Primary antibodies were
followed by horseradish peroxidase-conjugated goat anti–rabbit or
mouse IgG (Perkin Elmer, Boston, MA) as appropriate. Proteins
were detected by enhanced chemiluminescent substrate (Perkin
Elmer, Boston, MA). Mean intensity values were calculated using
ImageJ software (http://rsbweb.nih.gov/ij/).
RT-PCR of mRNA
Total RNA was extracted from tissues using TRIzol (Invitrogen)
according to the manufacturer’s specifications. mRNA was
transcribed using the Super ScriptIII (Invitrogen) reverse tran-
scriptase-polymerase chain reaction (RT-PCR) kit (Qiagen,
Mississauga, ON, Canada) and the PCR machine (Roche
Diagnostics, Laval, QC, Canada).
Primers
Oligo-nucleotides were synthesized by Sigma (Sigma, Oakville,
ON, Canada) and sequences are as follows:
b-Actin was used as control of 187bp as forward, 59-
AGGTGACAGCATTGCTTCTG-39 and reverse, 59-GCTGC-
CTCAACACCTCAAC-39. Interleukin-6 (IL-6) forward, 59- TC-
CAGTTGCCTTCTTGGGAC -39 and reverse, 59- GTGTAAT-
TAAGCCTCCGACTTG-39 with size of fragment as 140 bp.
Tumor necrosis factor-alpha (TNF-a) forward 59- CCTGTAG-
CCCACGTCGTAGC -39 and reverse, 59- TTGACCTCAG-
CGCTGAGTTG -39 with size of fragment as 373 bp. Interferon-
gamma (IFN-c) forward 59-TGGAGGAACTGGCAAAAGG-
ATG -39, and reverse 59-CGCTTCCTGAGGCTGGATTC -39,
with size of fragment as 289 bp. Interleukin-12b-p40 (IL-12b-p40)
forward 59-AGATGACATCACCTGGACCTCAG -39, and re-
verse 59- ACGTGAACCGTCCGGAGTAA -39, with size of
fragment as 230 bp.
Interleukin 23 receptor (IL-23R) forward, 59-TCCACTGACT-
CACTGCAAGG -39 and reverse 59-GTTCGTGGGAT-
GATTTTGCT -39, with size of fragment as 500 bp.
Serum Cytokine Analysis
Serum levels for IL-6, TNF-a,I F N - c, and IL-12p40 were
measured using Bio-Plex Pro Mouse Cytokine Multiplex Assay
(Bio-Rad Laboratories, Hercules, CA, USA) as per manufacturer’s
protocol with some minor modifications. In brief, 25 mlo fp r e - m i x e d
beads coated with capture antibodies were added to a 96-well plate.
Beads were washed twice and 25 ml of standards and serum (diluted
4-fold) were added to the wells before incubating on a microtiter
plate shaker at 300 rpm, protected from light, for one hour at room
temperature. Beads were washed three times, followed by the
addition of 12.5 ml of detection antibodies. The plate was incubated
as before. After three washes, 25 ml of streptavidin-phycoerythrin
wereadded to eachwelland incubated asbeforeforonly10minutes.
Beads were resuspended in 62.5 ml Bio-Plex Assay buffer on the
shaker at 300 rpm. Beads were read using the Bio-Plex Reader (Bio-
Rad Laboratories, Hercules, CA) and data was analyzed with Bio-
Plex Manager 2.0 software (Bio-Rad Laboratories, Hercules, CA).
Statistical Analysis
A linear-mixed model was employed and log likelihood was
used to test significance between genotypes by treatment over time
using R Statistical Package (R Development Core Team, http://
www.r-project.org/).
Histograms represent mean 6 standard error of the mean
(SEM). P values were determined using a one-way ANOVA using
Tukey-Kramer Multiple Comparisons.
Acknowledgments
The authors would like to thank Dr Claudio Fiocchi for constructive
comments on this manuscript as well as Dr. Vicky Marcus for pathological
analysis, Mr Joseph J. Bowden for statistical analysis, Dr Laurent Lessard
and Ms. Marianne Filion for their help in providing the immunohisto-
chemistry protocol, Mrs. Ailsa C. Lee Loy and members of the Tremblay
laboratory for critical support and helpful discussions.
Author Contributions
Conceived and designed the experiments: SWH DC MLT. Performed the
experiments: SWH KMD SH. Analyzed the data: SWH KMD SH NU
DC MLT. Contributed reagents/materials/analysis tools: NU DC MLT.
Wrote the paper: SWH DC MLT.
IBD with DSS in TC-PTP
+/2 Mice
PLoS ONE | www.plosone.org 6 January 2010 | Volume 5 | Issue 1 | e8868References
1. Franke A (2007) Systematic association mapping identifies NELL1 as a novel
IBD disease gene. PLoS ONE 2(8): e691.
2. The Wellcome Trust Case Control Consortium (2007) Genome-wide association
study of 14,000 cases of seven common diseases and 3,000 shared controls.
Nature 447: 661–678.
3. Franke A (2008) Replication of signals from recent studies of Crohn’s disease
identifies previously unknown disease loci for ulcerative colitis. Nat Genet.
4. Glinsky G (2008) An SNP-guided microRNA map of fifteen common human
disorders identifies a consensus disease phenocode aiming at principal
components of the nuclear import pathway. Cell Cycle 7: 2570–2583.
5. Wu F (2008) MicroRNAs are differentially expressed in ulcerative colitis and
alter expression of macrophage inflammatory peptide-2 alpha. Gastroenterology
135: 1624–1635.
6. Barrett JC (2008) Genome-wide association defines more than 30 distinct
susceptibility loci for Crohn’s disease. Nat Genet.
7. Fisher S (2008) Genetic determinants of ulcerative colitis include the ECM1
locus and five loci implicated in Crohn’s disease. Nat Genet.
8. Heinonen KM, Nestel FP, Newell EW, Charette G, Seemayer TA, et al. (2004)
T-cell protein tyrosine phosphatase deletion results in progressive systemic
inflammatory disease. Blood 103: 3457–3464.
9. Doody KM, Bourdeau A, Tremblay ML (2009) T-cell protein tyrosine
phosphatase is a key regulator in immune cell signaling: lessons from knockout
mouse model and immplications in human disease. Immunological Reviews 228:
325–341.
10. You-Ten KE (1997) Impaired Bone Marrow Microenvironment and Immune
Function in T Cell Protein Tyrosine Phosphatase–deficient Mice. J Exp Med
186: 683–693.
11. Heinonen KM, Dube N, Bourdeau A, Lapp WS, Tremblay ML (2006) Protein
tyrosine phosphatase 1B negatively regulates macrophage development through
CSF-1 signaling. Proc Natl Acad Sci U S A 103: 2776–2781.
12. Cool DE, Tonks NK, Charbonneau H, Walsh KA, Fischer EH, et al. (1989)
cDNA isolated from a human T-cell library encodes a member of the protein-
tyrosine-phosphatase family. Proc Natl Acad Sci USA 86: 5257–5261.
13. Mosinger B Jr, Tillmann U, Westphal H, Tremblay ML (1992) Cloning and
characterization of a mouse cDNA encoding a cytoplasmic protein-tyrosine-
phosphatase. Proc Natl Acad Sci USA 89: 499–503.
14. Sakaguchi AY, Sylvia VL, Martinez L, Smith EA, Han ES, et al. (1992)
Assignment of tyrosine-specific T-cell phosphatase to conserved syntenic groups
on human chromosome 18 and mouse chromosome 18. Genomics 12: 151–154.
15. Sasaki S, Yoneyama H, Suzuki K, Suriki H, Aiba T, et al. (2002) Blockade of
CXCL10 protects mice from acute colitis and enhances crypt cell survival.
Eur J Immunol 32: 3197–3205.
16. Malago JJ, Nondoli H (2008) Sodium arsenite reduces severity of dextran sulfate
sodium-induced ulcerative colitis in rats. J Zhejiang Univ Sci B 9(4): 341–350.
17. Nielsen OH, Kirman I, Rudiger N, Hendel J, Vainer B (2003) Upregulation of
interleukin-12and-17inactiveinflammatoryboweldisease.ScandJGastroenterol
38: 180–185.
18. Horie Y, Ma T (2004) Endotoxin-mediated disturbance of hepatic cytochrome
P450 function and development of endotoxin tolerance in the rat model of
dextran sulfate sodium-induced experimental colitis. Drug Metabolism and
Disposition 32: 437–441.
19. Balding J, Livingstone WJ, Conroy J, Mynett-Johnson L, Weir DG, et al. (2004)
Inflammatory bowel disease: the role of inflammatory cytokine gene polymor-
phisms. Mediators Inflamm 13: 181–187.
20. Podolsky DK (2002) Inflammatory bowel disease. N Engl J Med 347: 417–429.
21. Shanahan F (2002) Crohn’s disease. Lancet 359: 62–69.
22. Atreya R, Mudter J, Finotto S, Mulberg J, Jostock T, et al. (2000) Blockade of
IL-6 transsignalling abrogates established experimental colitis in mice by
suppression of T cell resistance against apoptosis. Journal of Allergy and Clinical
Immunology 105: S29–S29.
23. Mudter J, Neurath MF (2007) Il-6 signaling in inflammatory bowel disease:
pathophysiological role and clinical relevance. Inflamm Bowel Dis 13:
1016–1023.
24. Kerr J (1995) Jaks and Stats in signaling by the cytokine receptor superfamily.
Trends Genet 11: 69–74.
25. Simoncic PD, Loy A-L, Barber DL, Tremblay ML, McGlade CJ (2002) The T
cell protein tyrosine phosphatase is a negative regulator of janus family kinases 1
and 3. Curr Biol 12: 446–453.
26. ten Hove J, de Jesus Ibarra-Sanchez M, Fu Y, Zhu W, Tremblay ML (2002)
Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol Cell Biol 22:
5662–5668.
27. Yamamoto T, Sekine Y, Kashima K, Kubota A, Sato N, et al. (2002) The
nuclear isoform of protein-tyrosine phosphatase TC-PTP regulates interleukin-
6-mediated signaling pathway through STAT3 dephosphorylation. Biochem
Biophys Res Commun 297: 811–817.
28. Heinonen KM, Nestel FP, Newell EW, Charette G, Seemayer TA, et al. (2004)
T-cell protein tyrosine phosphatase deletion results in progressive systemic
inflammatory disease. Blood 103(109): 3457–3464.
29. van Vliet C, Bukczynska PE, Puryer MA, Sadek CM, Shields BJ, et al. (2005)
Selective regulation of tumor necrosis factor-induced Erk signaling by Src family
kinases and the T cell protein tyrosine phosphatase. Nat Immunol 6: 253–260.
30. Fitzpatrick LR Wang J, Le M (2000) In vitro and in vivo effects of gliotoxin, a
fungal metabolite: Efficacy against dextran sodium sulfate-induced colitis in rats.
Dig Dis Sci 45:45: 2327–2336.
31. McCafferty DM, Miampamba M, Sihota E, Sharkey KA, Kubes P (1999) Role
of inducible nitric oxide synthase in trinitrobenzene sulphonic acid induced
colitis in mice. Gut 45: 864–873.
32. Roviezzo F, Bucci M, Delisle C, Brancaleone V, Di Lorenzo A, et al. (2006)
Essential requirement for sphingosine kinase activity in eNOS-dependent NO
release and vasorelaxation. Faseb J 20: 340–342.
33. Gu F (2003) Protein tyrosine phosphatase 1B attenuates growth hormone-
mediated JAK2-STAT signaling. Mol Cell Biol. pp 3753–3762.
IBD with DSS in TC-PTP
+/2 Mice
PLoS ONE | www.plosone.org 7 January 2010 | Volume 5 | Issue 1 | e8868